- Do, and should, commissioners fund where the risk of marginal benefit over current treatment exists?
- How do research funders, including charities and governments, prioritise scarce resources?
- What clinical evidence will developers be providing to justify investment in their research, and once products are on the market?
Following on from the discussion, there will be a networking reception with Christmas themed refreshments.
Dr Virginia Warren
Virginia Warren is an acute services public health physician with special interests in rapid new health technology appraisal and clinical horizon scanning. She has developed the group of algorithms that Bupa uses to structure the evaluation of new or unusual tests or treatments, including one for cell based therapies. That was produced and piloted as part of Bupa’s involvement with the UK Department of Business, Innovation and Skills’ Technology Strategy Board VALUE project on the value chain from good idea to regenerative medicine product in routine use in healthcare. Experience in the project also indicated when it is appropriate to use the interventional procedures or medicines algorithms for regenerative medicine products.
Gin graduated MB BChir from the University of Cambridge, later gaining an MD for research in gastroenterology. She gained her membership (later fellowship) of the Faculty of Public Health whilst on the East Anglian training rotation. As young consultant she contributed to the UK’s debate about genetics-and-insurance, sitting on both the Joint Medical Royal Colleges Committee on Medical Genetics and the Association of British Insurers’ genetics committee. Outside work, she is a governor of The Perse School, Cambridge and a trustee of East Anglia’s Children’s Hospices
Clare Robinson, PhD DEBRA International Research Manager
Clare gained a BSc in Microbiology from Sheffield University in 1981, and a PhD in molecular microbiology from Dundee University, before holding a demonstratorship teaching biochemistry to preclinical medical students, and a virology post-doc, in St Andrews University. A move south in 1989 to Elsevier publishers in Cambridge, as Editor of Trends in Biotechnology, was followed by an appointment in Public Understanding of Science, focusing on genetic modification of food crops, at the John Innes Centre in Norwich. Two similar roles in liaising between academia and bioindustry, and promoting the biopharma sector, in the SW and then the SE of England regional development agencies, was followed by a move to the charitable sector, working with DEBRA UK and DEBRA International since 2006.
Prof Molly Stevens
Molly Stevens is currently Professor of Biomedical Materials and Regenerative Medicine and the Research Director for Biomedical Material Sciences in the Institute of Biomedical Engineering at Imperial College. She joined Imperial in 2004 after a Postdoctoral training in the laboratory of Professor Robert Langer in the Chemical Engineering Department at the Massachusetts Institute of Technology (MIT)n 2010 she was recognised by The Times as one of the top ten scientists under the age of 40 and also received the Polymer International-IUPAC award for creativity in polymer science, the Rosenhain medal and the Norman Heatley Prize for Interdisciplinary research from the Royal Society of Chemistry.
You can find out all about the Healthcare Special Interest Group and previous events here.
This is a ticket only event and all guests must pre-register.